Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY20 results · Apr–Jun 2019
Gufic Biosciences reported revenue from operations of ₹92.39 crore (up 17.7% from Q1 FY19) and net profit of ₹6.81 crore (up 73.2% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a standalone basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 92.39 | 78.49 | +17.7% | 91.55 | +0.9% |
| Other income | 1.02 | 0.22 | +354.5% | 3.29 | −68.9% |
| Total income | 93.41 | 78.72 | +18.7% | 94.83 | −1.5% |
| Profit before tax | 9.19 | 6.52 | +40.9% | 10.75 | −14.5% |
| Net profit for the period | 6.81 | 3.93 | +73.2% | 6.01 | +13.2% |
| EPS, basic (₹) | 0.88 | 0.51 | +72.5% | 0.77 | +14.3% |
| Net margin (%) | 7.4 | 5.0 | 6.6 |
Standalone
- Filed with BSE
- 17 Aug 2019, 12:28 IST
- Board meeting
- 13 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE